Literature DB >> 20348929

Hypertension: Endothelin-receptor antagonists for treating hypertension.

Matthew R Weir.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20348929     DOI： 10.1038/nrneph.2010.14

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

1.  Increased plasma endothelin level in patients with essential hypertension.

Authors:  Y Saito; K Nakao; M Mukoyama; H Imura
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

Review 2.  Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.

Authors:  Matthew R Weir; Mark Rolfe
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-11       Impact factor: 8.237

Review 3.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

4.  Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

Authors:  René R Wenzel; Thomas Littke; Susan Kuranoff; Christiane Jürgens; Heike Bruck; Eberhard Ritz; Thomas Philipp; Anna Mitchell
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

5.  Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.

Authors:  J Smolander; B Vogt; M Maillard; C Zweiacker; T Littke; T Hengelage; M Burnier
Journal:  Clin Pharmacol Ther       Date:  2009-03-11       Impact factor: 6.875

6.  Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.

Authors:  Krishna K Gaddam; Mari K Nishizaka; Monique N Pratt-Ubunama; Eduardo Pimenta; Inmaculada Aban; Suzanne Oparil; David A Calhoun
Journal:  Arch Intern Med       Date:  2008-06-09

7.  A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

Authors:  Michael A Weber; Henry Black; George Bakris; Henry Krum; Stuart Linas; Robert Weiss; Jennifer V Linseman; Brian L Wiens; Marshelle S Warren; Lars H Lindholm
Journal:  Lancet       Date:  2009-09-11       Impact factor: 79.321

8.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.